SOURCE: INSYS Therapeutics

Insys Therapeutics

April 22, 2014 16:30 ET

Insys Therapeutics to Present at 39th Annual Deutsche Bank Health Care Conference

PHOENIX, AZ--(Marketwired - Apr 22, 2014) - Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will present at the 39th Annual Deutsche Bank Health Care Conference on May 7 - 8, 2014 at the InterContinental Hotel in Boston, MA.

Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will host the presentation on Thursday, May 8, 2014 at 2:50 p.m. EDT.

To listen to the audio webcast of this presentation during the event, please visit: www.insysrx.com. A replay of this webcast will be available for 30 days after the initial presentation.

About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.

Contact Information